Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
Key Highlights
- ➤Shattuck Labs announced two poster presentations at UEG Week 2026.
- ➤SL-846 presentation covers a half-life extended DR3 x IL23RA bispecific antibody.
- ➤TL1A immune-complex presentation addresses anti-drug antibodies cross-binding approved IBD antibodies.
- ➤Presentations are scheduled for October 17–20, 2026, in Barcelona.
Expert Statements
Mahmud Hussain, Director, R&D of Shattuck Labs
“Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody”
Suresh de Silva, Chief Scientific Officer of Shattuck Labs
“Soluble TL1A/Anti-TL1A Immune Complexes Induce De Novo Production of TL1A and Induce Anti-Drug Antibodies That Cross-Bind Approved IBD Antibodies”
AUSTIN, Texas and DURHAM, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced two upcoming poster presentations at United European Gastroenterology (UEG) Week 2026, taking place October 17–20, 2026, in Barcelona, Spain.
Format: Moderated poster presentation Title: Development and Characterization of SL-846: A Half-Life Extended, Dual-Receptor (DR3 x IL23RA) Targeting Bispecific Antibody Presenter: Mahmud Hussain, Ph.D., Director, R&D of Shattuck Labs Date/Time: October 19, 2026; 1:00–2:00 p.m. CEST
Get started
Create a free account to read the full story.